Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Medical Research
Articles
Primary care gets a new approach: prevention
A budding model for primary care that encourages the family doctor to act as a health coach who focuses as much on preventing illness as on treating it has shown promising results and saved insurers millions of dollars.
Roche wins as high court limits university patent rights
Monday's Supreme Court decision is a victory for companies that collaborate with universities in research. Indianapolis-based Eli Lilly and Co. was among the companies that supported Roche.
Brain barrier breached in push to deliver Alzheimer’s drug
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s disease.
China making big gains in drug R&D jobs state covets
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
Regulators delay approval of Lilly’s Alzheimer’s screen
The Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
Research jobs could flow from Purdue quad
Purdue University officials and others connected with the life sciences in Indiana say the planned $164 million Life and Health Sciences Quadrangle at the West Lafayette campus will mean high-paying jobs, retention of highly skilled scientists, and researchers who might well have left the state for either coast.
Lilly collaboration with outside researchers yields first deal
Eli Lilly and Co.’s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it’s just the first of many such collaborations.
Endocyte again changes terms of public offering
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Lilly imaging drug isn’t ready for approval, FDA says
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer’s disease isn’t ready for approval, according to U.S. regulators.
Lilly’s Solpura may lack data to prove effectiveness
Outside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency caused by cystic fibrosis, chronic pancreatitis or other conditions.
Lilly, other big drugmakers shut out by FDA in 2010
Regulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer Inc., the world’s largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same time, according to agency records.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Q&A
Molecular biologist,David G. Skalnik will become associate dean for research and graduate education at the IUPUI School of Science in January. Since 1991, Skalnick has been a researcher at the Indiana University School of Medicine, leading a team of three in the study of epigenetics—factors that influence whether certain genes are turned on or turned off.
Lilly, Acrux receive FDA approval for Axiron
The companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year in the United States.
Study: Arthritis drug co-developed by Lilly shows promise
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Lilly makes $300M deal for Philadelphia drug company
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.